GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy

Stopped early

Conditions studied: Breast Cancer

In brief

The purpose of this study is to test the ease of using a new device, called the GlowCap that reminds the patient to take their breast cancer hormone pill. The study will collect information about the experience with this device and what the patient thinks of its role in the daily pill taking routine.

Key facts

Study ID

NCT01239251

Run by

Memorial Sloan Kettering Cancer Center

People needed

8

Starts

2010-11-01

Expected to finish

2011-11-01

Last updated by the study team

2015-03-06

Who can join

Age: 60 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen, anastrozole, letrozole, exemestane).
• Age ≥ 60 years
• Must have broadband internet access at home (to enable the base for the system to communicate to the Vitality server).
• Must have a landline or mobile phone

You may not qualify if…

• Non-English speaking patients

Where it is running

• Memorial Sloan Kettering Cancer Center 1275 York Avenue — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.